Mednow（MDNW.F）株式概要ヘルスケア企業のMednow Inc.は、独自のウェブ・モバイル・アプリケーションを開発・運営し、カナダにおける処方薬の販売・流通、バーチャル・ケア、遠隔医療サービス、医師の訪問診療を促進している。 詳細MDNW.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去 1 年間で収益は359.2%増加しましたリスク分析マイナスの株主資本 株式の流動性は非常に低い 意味のある時価総額がありません ( $25 )最新の財務報告は1年以上前のものである すべてのリスクチェックを見るMDNW.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.000001100.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-26m42m2016201920222025202620282031Revenue CA$41.6mEarnings CA$1.2mAdvancedSet Fair ValueView all narrativesMednow Inc. 競合他社Colabor GroupSymbol: OTCPK:COLF.FMarket cap: US$1.0kRidgetechSymbol: NasdaqCM:RDGTMarket cap: US$193.8kHealthWarehouse.comSymbol: OTCPK:HEWAMarket cap: US$7.7mMangoceuticalsSymbol: NasdaqCM:MGRXMarket cap: US$7.0m価格と性能株価の高値、安値、推移の概要Mednow過去の株価現在の株価US$0.00000152週高値US$0.2652週安値US$0.000001ベータ1.941ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-100.00%最新ニュースお知らせ • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.お知らせ • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.お知らせ • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.お知らせ • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.お知らせ • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.お知らせ • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.最新情報をもっと見るRecent updatesお知らせ • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.お知らせ • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.お知らせ • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.お知らせ • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.お知らせ • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.お知らせ • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.お知らせ • Jul 29Mednow Inc. announced that it expects to receive CAD 0.4 million in fundingMednow Inc. announced private placement of a secured convertible debenture for gross proceeds of CAD 400,000 on July 28, 2023. The transaction will include participation from Ali Reyhany, the Chief Executive Officer of the company. The debenture will bear interest at a rate of 12.0% per annum and mature 18 months following the date of issuance. The principal amount of the convertible debenture will be convertible into 5,263 units based on a conversion price of CAD 0.30 per unit. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.38 per common share for a period of 48 months from the date of issuance thereof, subject to applicable policies of the TSX Venture Exchange. The convertible debenture will be convertible at the option of the holder at any time during the period beginning on the later of the four month anniversary of the date of issuance of the convertible debenture; and the date on which the company completes an equity financing with aggregate proceeds to the company of at least CAD 4,000,000, and ending on the maturity date. The debenture will rank senior, secured by all of the assets and property of the company. The debenture to be issued pursuant to the transaction are subject to a statutory hold period of four months from the date of issuance. The transaction remains subject to receipt of TSX Venture Exchange approval and all other necessary regulatory approvals.お知らせ • May 17Mednow Inc. announced that it expects to receive CAD 0.585 million in fundingMednow Inc. announced a non-brokered private placement of up to 2,166,667 units at a price of CAD 0.27 per unit for the gross proceeds of CAD 585,000 on May 15, 2023. The transaction included participation from individual investor, Ali Reyhany for CAD 300,000. The Company paid finder’s fees of $23,400, issued 86,666 finder’s warrants and paid a fiscal advisory fee through the issuance of 86,666 units. Each Finder’s warrant is exercisable to acquire one unit at the unit price for a period of 5 years from the Closing Date. All securities issued pursuant to the Private Placement will be subject to a four-month hold period from the date of issuance.お知らせ • May 16Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million.Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million. Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0216 Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0108お知らせ • Jan 24Mednow Inc. Supports Expanded Scope of Practice for Ontario PharmacistsMednow Inc. is supportive of the new expanded scope of practice for Ontario pharmacists. As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions. These conditions include: hives, cold sores, urinary tract infections and pink eye, among others. These services are available for patients with a valid Ontario health card. There is no out-of-pocket charge for patients as this initiative is publicly funded. The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing. The existing Nurse Practitioner led Mednow Virtual Care service has been issuing prescriptions where appropriate, ordering lab work and making referrals at no cost to Mednow patients. The interdisciplinary and digital first model of patient care has been successful in providing convenient and accessible care to the patients. Pharmacists prescribing for these minor ailments will provide not only improved team based care for the clients, but realizes cost savings in wages and open a new revenue stream into the existing built infrastructure for Mednow, who will be reimbursed under the Ontario Drug Benefits Program for these prescribing services. This new service available at Mednow complements the recently announced pharmacist in-home medication cabinet clean up and medication review program. Mednow believes patients can receive amazing care in limited circumstances and as governments lean more and more on allied healthcare to help the stressed system, Mednow will be at the forefront of this evolution. Minor ailments can often be managed with self-care strategies and minimal treatment or follow-up required. Pharmacists can offer timely services to patients, helping Ontarians avoid wait times.お知らせ • Jan 18Mednow Inc. Expands Suite of ServicesMednow Inc. has expanded its suite of services to its at-home Medvisit and other patients. Medvisit's expanded suite of services includes an at-home medication review program for patients who are not physically able to attend a community pharmacy. The addition of the at-home medication review program, conducted by team of licensed traveling pharmacists, allows the physician who will see the patient afterwards to focus on treating the patient and not on performing a medication history. Pharmacists are experts in drug therapy and can help as part of the medical team to make processes more efficient. The service is covered for eligible and consenting patients by the Ontario Drug Benefits Program. It is an example of non-dispensing related revenue available to pharmacies in Canada's largest province. Medvisit is Canada's largest and longest standing doctor house call service, having been in operation for over 30 years. Medvisit conducts approximately 30,000 patient home visits per year and has served over 400,000 patients since inception. Patients that are unable to leave their home rely on over 100 doctors in the Medvisit network for the treatment of acute and episodic illness and injury. The combination of pharmacy and doctor home visits through the Mednow platform has created synergies that greatly benefit patients. By offering a comprehensive review of their medications and treatment plan prior to in-home medication visits, Mednow and Medvisit are able to provide the highest level of care at the forefront of chronic disease management. Through the Medvisit patient network, Mednow is well positioned to offer a full platform of services to a large subset of patients that can benefit greatly from a full suite of digital healthcare and delivery services. Mednow is focused on improving delivery of pharmacy services in Canada through digitization to provide better patient access to pharmacists, doctors and other healthcare professionals. Mednow offers instant access to pharmacists in the Mednow app (Apple | Android | web browser) or on the phone (1-855-MEDNOW-1) and offers fast, free delivery of prescription medication to patients across Canada.株主還元MDNW.FUS Consumer RetailingUS 市場7D0%0.9%-0.3%1Yn/a21.5%26.7%株主還元を見る業界別リターン: MDNW.FがUS Consumer Retailing業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: MDNW.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is MDNW.F's price volatile compared to industry and market?MDNW.F volatilityMDNW.F Average Weekly Movementn/aConsumer Retailing Industry Average Movement5.3%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: MDNW.F 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のMDNW.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2018n/an/amednow.caヘルスケア企業のMednow Inc.は、独自のウェブ・モバイル・アプリケーションを開発・運営し、カナダにおける処方薬の販売・流通、バーチャル・ケア、遠隔医療サービス、医師の在宅訪問を促進している。また、ブリティッシュ・コロンビア州とオンタリオ州に位置するMednow Pharmacyの名称で小売薬局を所有・運営している。同社は2018年に法人化され、カナダのバンクーバーに本社を置いている。もっと見るMednow Inc. 基礎のまとめMednow の収益と売上を時価総額と比較するとどうか。MDNW.F 基礎統計学時価総額US$25.00収益（TTM）-US$19.10m売上高(TTM)US$30.38m0.0xP/Sレシオ0.0xPER（株価収益率MDNW.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MDNW.F 損益計算書（TTM）収益CA$41.57m売上原価CA$36.67m売上総利益CA$4.90mその他の費用CA$31.03m収益-CA$26.13m直近の収益報告Apr 30, 2023次回決算日該当なし一株当たり利益（EPS）-1.01グロス・マージン11.78%純利益率-62.87%有利子負債／自己資本比率-90.6%MDNW.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/29 04:26終値2024/04/01 00:00収益2023/04/30年間収益2022/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mednow Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.
お知らせ • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.
お知らせ • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.
お知らせ • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.
お知らせ • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.
お知らせ • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.
お知らせ • Nov 03Mednow Announces Notice Received from Secured CreditorMednow Inc. announced that it has received a notice of default, demand and intention to enforce security from its related secured creditor Alirey Corp. amounting to $3.23 million. Mednow intends to cooperate with secured creditor to facilitate a transitional plan.
お知らせ • Oct 31+ 1 more updateMednow Announces Executive ChangesMednow Inc. announces that Ali Reyhany has stepped down as CEO, President and Director. Felipe Campusano has also resigned as a Director, Treasurer and Secretary.
お知らせ • Oct 24Mednow Inc. announced that it has received CAD 0.85 million in fundingOn October 23, 2023 Mednow Inc. closed the transaction. The company has amended the terms of the transaction and received gross proceeds of CAD 850,000. Ali Reyhany, CEO and Co-Founder, invested CAD 850,000 pursuant to the Offering.
お知らせ • Sep 20Mednow Inc. Announces the Execution of Cost Reductions Through the Wind-Down of A SubsidiaryMednow Inc. announced that Infusicare Inc. has permanently ceased ordinary course business operations. Infusicare’s shutdown is part of Mednow’s ongoing efforts to improve its business by, among other things, eliminating underperforming business lines, in accordance with its previous announcements. Mednow has also received a demand letter from a supplier for $1.5 million. Mednow is in continued discussions with the supplier.
お知らせ • Sep 05Mednow Announces Board Member ResignationsMednow Inc. announced that Kia Besharat and Mahdi Shams have stepped down as directors of the company to pursue other opportunities.
お知らせ • Aug 03Mednow Inc. announced that it has received CAD 0.4 million in fundingOn August 1, 2023, Mednow Inc. closed the transaction.
お知らせ • Jul 29Mednow Inc. announced that it expects to receive CAD 0.4 million in fundingMednow Inc. announced private placement of a secured convertible debenture for gross proceeds of CAD 400,000 on July 28, 2023. The transaction will include participation from Ali Reyhany, the Chief Executive Officer of the company. The debenture will bear interest at a rate of 12.0% per annum and mature 18 months following the date of issuance. The principal amount of the convertible debenture will be convertible into 5,263 units based on a conversion price of CAD 0.30 per unit. Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of CAD 0.38 per common share for a period of 48 months from the date of issuance thereof, subject to applicable policies of the TSX Venture Exchange. The convertible debenture will be convertible at the option of the holder at any time during the period beginning on the later of the four month anniversary of the date of issuance of the convertible debenture; and the date on which the company completes an equity financing with aggregate proceeds to the company of at least CAD 4,000,000, and ending on the maturity date. The debenture will rank senior, secured by all of the assets and property of the company. The debenture to be issued pursuant to the transaction are subject to a statutory hold period of four months from the date of issuance. The transaction remains subject to receipt of TSX Venture Exchange approval and all other necessary regulatory approvals.
お知らせ • May 17Mednow Inc. announced that it expects to receive CAD 0.585 million in fundingMednow Inc. announced a non-brokered private placement of up to 2,166,667 units at a price of CAD 0.27 per unit for the gross proceeds of CAD 585,000 on May 15, 2023. The transaction included participation from individual investor, Ali Reyhany for CAD 300,000. The Company paid finder’s fees of $23,400, issued 86,666 finder’s warrants and paid a fiscal advisory fee through the issuance of 86,666 units. Each Finder’s warrant is exercisable to acquire one unit at the unit price for a period of 5 years from the Closing Date. All securities issued pursuant to the Private Placement will be subject to a four-month hold period from the date of issuance.
お知らせ • May 16Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million.Mednow Inc. has completed a Composite Units Offering in the amount of CAD 0.525262 million. Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0216 Security Name: Units Security Type: Equity/Derivative Unit Price\Range: CAD 0.27 Discount Per Security: CAD 0.0108
お知らせ • Jan 24Mednow Inc. Supports Expanded Scope of Practice for Ontario PharmacistsMednow Inc. is supportive of the new expanded scope of practice for Ontario pharmacists. As of January 1st, pharmacists in Ontario are now able to better support patients by assessing and prescribing treatment for 13 minor conditions. These conditions include: hives, cold sores, urinary tract infections and pink eye, among others. These services are available for patients with a valid Ontario health card. There is no out-of-pocket charge for patients as this initiative is publicly funded. The expanded scope of practice for Ontario pharmacists will allow Mednow to expand its virtual care program to include pharmacist-led prescribing. The existing Nurse Practitioner led Mednow Virtual Care service has been issuing prescriptions where appropriate, ordering lab work and making referrals at no cost to Mednow patients. The interdisciplinary and digital first model of patient care has been successful in providing convenient and accessible care to the patients. Pharmacists prescribing for these minor ailments will provide not only improved team based care for the clients, but realizes cost savings in wages and open a new revenue stream into the existing built infrastructure for Mednow, who will be reimbursed under the Ontario Drug Benefits Program for these prescribing services. This new service available at Mednow complements the recently announced pharmacist in-home medication cabinet clean up and medication review program. Mednow believes patients can receive amazing care in limited circumstances and as governments lean more and more on allied healthcare to help the stressed system, Mednow will be at the forefront of this evolution. Minor ailments can often be managed with self-care strategies and minimal treatment or follow-up required. Pharmacists can offer timely services to patients, helping Ontarians avoid wait times.
お知らせ • Jan 18Mednow Inc. Expands Suite of ServicesMednow Inc. has expanded its suite of services to its at-home Medvisit and other patients. Medvisit's expanded suite of services includes an at-home medication review program for patients who are not physically able to attend a community pharmacy. The addition of the at-home medication review program, conducted by team of licensed traveling pharmacists, allows the physician who will see the patient afterwards to focus on treating the patient and not on performing a medication history. Pharmacists are experts in drug therapy and can help as part of the medical team to make processes more efficient. The service is covered for eligible and consenting patients by the Ontario Drug Benefits Program. It is an example of non-dispensing related revenue available to pharmacies in Canada's largest province. Medvisit is Canada's largest and longest standing doctor house call service, having been in operation for over 30 years. Medvisit conducts approximately 30,000 patient home visits per year and has served over 400,000 patients since inception. Patients that are unable to leave their home rely on over 100 doctors in the Medvisit network for the treatment of acute and episodic illness and injury. The combination of pharmacy and doctor home visits through the Mednow platform has created synergies that greatly benefit patients. By offering a comprehensive review of their medications and treatment plan prior to in-home medication visits, Mednow and Medvisit are able to provide the highest level of care at the forefront of chronic disease management. Through the Medvisit patient network, Mednow is well positioned to offer a full platform of services to a large subset of patients that can benefit greatly from a full suite of digital healthcare and delivery services. Mednow is focused on improving delivery of pharmacy services in Canada through digitization to provide better patient access to pharmacists, doctors and other healthcare professionals. Mednow offers instant access to pharmacists in the Mednow app (Apple | Android | web browser) or on the phone (1-855-MEDNOW-1) and offers fast, free delivery of prescription medication to patients across Canada.
